水分胁迫对小麦叶片光合作用的影响及其与抗旱性的关系

在水分胁迫初期,两个小麦品种叶片光合速率,气孔导度和细胞间隙CO_2浓度降低,气孔限制值增加,光合速率的降低主要是气孔因素的限制。中度到严重水分胁迫使叶片光合速率、气孔导度和气孔限制值降低,细胞间隙CO_2浓度明显增加,且叶圆片放氧能力,叶绿体Hill反应、叶绿素荧光强度和表观量子产额降低,此时光合速率的降低主要是叶肉细胞光合活性的下降引起的。抗旱性弱的郑引一号叶肉细胞光合活性比抗旱性强的丰抗13更容易受到水分胁迫的影响。     

北京山区封山育林试验研究效果

 本文报道了1984年在北京密云县古石峪进行的封山育林试验研究。五年中进行了三次复查,证明在植被盖度、灌木草本生物量、多样性指数方面都有增加。四类样地更新较好;两类阳坡干旱型样地更新不良,但引种栓皮栎获得成功。本研究还进行了山杨移根的试验。     

Gene technology-based antimetabolite design: the use of an in vitro protein expression system to facilitate antimetabolite design for virally-induced human diseases and malignant conditions

A precondition for the chemotherapeutic treatment of a variety of virally-induced human diseases and malignant conditions is a highly selective interaction of the drug molecule to be used with it's biological target. To ensure the development of novel, effective drugs, it is essential that the biological target is well characterised with regard to it's structure and activity. Such characterisation relies upon adequate amounts of pure target being available. One of the most important enzymatic importers for antimetabolites is the enzyme thymidine kinase. In this article an in vitro protein expression system is described which facilitates the production of milligram amounts of pure and biologically active thymidine kinase, from a number of important biological sources. Results have shown that the in vitro produced enzyme has the exact biochemical propeties of the in vivo enzyme. Thus the in vitro protein expression system is an ideal vechicle to facilitate an in depth investigation of the enzyme's biological properties.     

盘鮈属鱼类的分类研究及两新种记述(鲤形目:鲤科)

盘鮈属是我国鲤科鱼类的一个特有属,过去已记录7种,因早期发表的云南盘鮈原始描述简略,国内又无人察看过模式标本,造成一些种名归属混乱。本工作在核对多数种的模式标木或地模标本的基础上,对盘鮈属鱼类的分类性状重新估价,认为多鳞盘鮈 D.polylepis Huang不能成立,为长鳔盘鮈 D.macrophysallidos Huang的同物异名,予以归并,经整理本属鱼类可分为8个种,其中具2个新种,文中给出了分种检索表,还就过去分类中存在的其他问题进行了讨论。     

The Legislation for Biodiversity Conservation in China

Effectivebiodiverdityconservationneedsasoundlegalsystemthatincludesthelegisla-tionininternational,nationalandlocallevels.TheConventiononBiologicalDiversity(CBD)thatenteredintoforceonDecember29,1993,isaninternationallegalinstrument.Asaframeconvention,ithasformedalegalsystem,togetherwiththeotherinternationalagree-mentssuchastheConventiononWetlandsofInternationalImportanceEspeciallyasWater-fowlHabitat(Ramsar1971),theConventionConcerningtheProtectionoftheWorldCul-turalandNaturalHeritage(P…     

用地高辛标记探针检测基因工程人β干扰素制品中的外源DNA

基因工程人β干扰素工程菌经发酵培养、纯化后获得纯的制品,采用斑点杂交技术,用非放射性地高辛标记超声裂解的全工程菌ＤＮＡ作为探针,检测基因工程人β干扰素纯品,结果显示：基因工程人β干扰素纯品中的外源ＤＮＡ含量小于１００ｐｇ／剂。     

虎耳草科落新妇族的研究

本文探讨了落新妇族Trib．Astilbeae的系统发育和地理分布。依据进化论、被子植物性状演化总趋势和外类群比较,确认了该族及其外类群Penthorum的重要性状(染色体基数,花粉纹饰,胎座式,心皮、雄蕊、花瓣和萼片数目,萼片脉型,叶型)的极性。采用徐克学(1989)最大同步法做了分支分析,推导出了该族的系统树图。系统树图表明：Rodgersia和Astilboides是一单系类群,而Astilbe为其姊妹群; Rodgersia较Astilbe进化,Astilboides则居二者之间;Penthorum是落新妇族的姊妹群,且与之有共同祖先。迄今为止,已知落新妇族共有24种和13变种(原变种除外)。分布于Takhtajan(1986)的东亚区、大西洋-北美区、伊朗-土兰区和马来西亚区。在东亚区,日本、朝鲜和中国(吉林-辽宁东部)有3属、17种和变种,占该族种与变种总数的45．9％,其中,含有不同演化水平的类群和该族原始种有Astilbe platyphylla,A.simplicifolia和Rodgersia podophylla,此地区是该族的起源中心、现代分布中心和分化中心。 横断山地区有2属、11种和变种,占29．7％,是另一现代分布中心。本族较进化的种Astilbe biternata、A. indica、A.khasiana和Rodgersia nepalensis等,均出现于远离起源中心地区。据此推断,本族植物的散布路线可能是从日本、朝鲜和中国(吉林-辽宁东部)向北通过东西伯利亚和白令陆桥,继而向东南进入北美东南部;向南经中国南部至菲律宾和爪哇,向西南越秦岭-大巴山山地、横断山,入喜马拉雅。落新妇属 Astilbe和鬼灯檠属Rodgersia均分布于亚洲大陆和日本岛屿,而日本于晚第三纪以来,即与亚洲大陆分离,故落新妇属和鬼灯檠属的形成,当在日本与亚洲大陆分离之前。据此推知,落新妇族的起源时间可能在早第三纪,或可追溯至晚白垩纪。     

Search for the possible role of ‘immunotherapy’ in operable bronchial non-small cell carcinoma (stage I and II): A phase I study with Corynebacterium parvum intrapleurally

Summary The possibility of giving C. parvum intrapleurally (i.p.) was investigated. C. parvum was given post-operatively either i.p. only or i.p. and intravenously (i.v.) simultaneously. The dose varied from 0.1–10 mg i.p. All patients had been operated for a bronchial carcinoma. Results: (1) Subjective complaints of either dyspnoea, thoracic pain, chills or nausea occured in 31 of 63 patients. No clear dose relation was found. A feeling of discomfort and fever could occur for another 3–4 days after the above more acute symptoms had disappeared. (2) Increased fever (0.5° C) occurred in 71% of the patients injected i.p. only. (3) No anaphylactic reaction was observed. (4) Increased total white blood cell counts (<20%) occurred in 38 patients. The WBC increase was mainly due to higher number of neutrocytes and granulocytes. Total lymphocyte, monocyte, eosinophilic, and basophilic granulocytes values per mm³ circulating blood remained unchanged, except at the dose of 7 mg C. parvum i.p. when monocyte values were increased significantly from 576±247 to 1100±578/mm³. (5) Moderate to severe effusions were observed radiologically in three patients after C. parvum intrapleurally.The study group is: M. Kaufmann, J. Stjernswärd (Ludwig Institut for Cancer Research, Lausanne Branch, Switzerland), M. Zelen, K. Stanley (Frontier Science and Technology Research Foundation, Inc. Amherst, New York, USA), D. S. Freestone, R. Bomford, M. T. Scott, T. Priestman (The Wellcome Research Laboratory, Beckenham, England), C. Mouritzen, G. Ahlbom (Dept. of Thoracic and Cardiovascular Surgery, Aarhus Kommunehospital, Aarhus, Denmark), N. Konietzko, D. Greschuchna (Ruhrland Klinic, Essen-Haidhausen, Germany), P. Hilgard (Innere Klinik und Poliklinik [Tumorforschung] Essen, Germany), J. Vogt-Moykopf, D. Zeidler, H. Toomes (Thoraxchirurgische Spezial-Klinik, Heidelberg-Rohrbach, Germany), F. Krause, R. Rios (Thoraxchirurgische Abt., Fachkrankenhaus für Lungen- und Bronchialerkrankungen, Löwenstein, Germany), J. Orel, M. Benedik, B. Hrabar (Clinical Center, Dept. of Thoracic Surgery, Ljubljana, Yugoslavia), S. Plesnicar (The Institute of Oncology, Ljubljana, Yugoslavia), H. A. Rostad, J. R. Vale (Rikshospital, Oslo, Norway), S. Hagen, S. Birkeland, (Ulleval Hospital, Oslo, Norway), T. Harbitz, R. Nissen-Meyer (Aker Hospital, Oslo, Norway), L. Rodriguez, V. O. Björk, K. Böök (Karolinska Sjukhuset, Thoracic Clinic, Stockholm, Sweden), E. Gradel, J. Hasse, P. Holbro (Kantonsspital, Thoraxchirurgische Klinik, Basel, Switzerland), L. Eckmann (Tiefenauspital, Chir. Univ.-Klinik, Bern, Switzerland), B. Nachbur, T. Liechti (Inselspital, Dept. of Thoracic and Cardiovascular Surgery, Bern, Switzerland), H. Cottier (Inst. of Pathology, Inselspital, Bern, Switzerland), W. Maurer, M. Kaufmann, P. Froelicher (Bürgerspital, Surgical Dept., Solothurn, Switzerland), H. Denck, N. Pridun (Krankenhaus der Stadt Wien-Lainz, Chir. Abt., Vienna, Austria), K. Karrer (Institute for Cancer Research, University of Vienna, Austria) Reprint requests should be addressed to any of the members listed above, or to the Ludwig Lung Cancer Trial, Operation Office, LICR, CH-1066 Epalinges, Switzerland. (For Current Contents, etc., please use above address)